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Identity 
Other names: CD107B; EC 1.13.11.52; IDO; INDO 




The human IDO1 gene is encoded on 10 exons which 
span 14,163 bps at chromosome 8p12-p11 (nucleotides 
39,890,485-39,905,107). The murine IDO1 gene is 
similarly sized and localized to a syntenic locus on 
mouse chromosome 8A2. 
Transcription 
Transcription of the human IDO1 gene produces a full-
length mRNA transcript of 1,572 nt. The promoter 
includes transcription factor sites that confer 
responsiveness to type I and type II interferons (IFN-
alpha / IFN-beta and IFN-gamma respectively), most 
potently to IFN-gamma. Many cell types strongly 
increase IDO transcription after exposure to IFN-
gamma, including myeloid cells 
(monocyte/macrophages and dentritic cells), 
fibroblasts, endothelial cells, epithelial cells and many 
tumor cell lines. STAT and IRF transcription factors 
function cooperatively to mediate induction of IDO1 
expression by IFN-gamma, and mice lacking either 
IFN-gamma or IRF1 function are deficient in IDO1 








The IDO1 gene encodes a full-length protein of 403 
amino acids with a predicted molecular weight of 
45,332 Daltons. The open reading frame is preceded by 
a long, untranslated sequence. There is no Kozak 
consensus sequence present at the ATG start site in th
open reading frame. 
Expression 
IDO1 is widely expressed in the body. High expression 
is seen in placental trophoblast giant cells of fetal 
origin, epididymis, gut (distal ileum and colon), lymph 
nodes, spleen, thymus and lung. IDO activity in many 
of these locations is markedly increased in vivo by LPS 
treatment. With the exception of epididymis, a common 
feature of sites of expression is extensive mucosal 
surfaces and/or large lymphoid compartments with 
immunoregula-tory roles. IDO1 is overexpressed in 
many human diseases including cancer, chronic 
infectious disease, allergy, autoimmune disease and 
other disorders characterized by local immune suppres-
sion. 
Localisation 
IDO1 is a cytosolic enzyme with no known secreted or 
extracellular form. 
Function 
IDO1 is a single-chain oxidoreductase catalyzing the
first, rate-limiting step of tryptophan degrada-tion in 
biosynthesis of the central metabolic regulator 
nicotinamide adenine dinucleotide (NAD) along the 
kynurenine pathway. In mammals, IDO1 does not  
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catabolyze excess dietary tryptophan, which is carried 
out by the liver enzyme TDO2, and NAD levels are not 
maintained by synthesis but by salvage from the diet. 
Thus, the role of IDO1 in mammals was obscure until it 
was discovered to be strongly induced by IFN-gamma 
and linked to immune control. The function of IDO1 in 
immune control is based on broad evidence that 
tryptophan depletion and/or kynurenine production 
suppresses T cell-mediated immunity. In particular, 
IDO1-mediated tryptophan catabolism in antigen-
presenting dendritic cells appears to be an important 
mechanism to generate immune tolerance to cross-
presented neoantigens, such as those that arise during 
allogeneic pregnancy or cancer. 
Antiproliferation: Tryptophan catabolism by IDO1 
has been suggested to mediate antiprolife-rative effects 
during infection, including directly on infectious 
microorganisms that may rely on trypto-phan for 
growth. With regard to the function of IDO1 in immune 
regulation, tryptophan depletion in the vicinity ofan 
antigen presentation event has been suggested to limi  
T cell activation by preventing the cell division 
required by T cells to become activated upon 
appropriate presentation of antigen. Dendritic cells 
arising from monocytes acquire the ability to act as 
regulatory cells that suppress T cell proliferation 
through tryptophan catabolism by IDO1. The 1-methyl 
analogue of tryptophan (1MT) has been used widely to 
block IDO activity. When T cells are deprived of 
tryptophan, they arrest at a mid-G1 phase of the cell 
cycle. Restoring tryptophan does not restore the 
activation process, which requires a second round of T 
cell receptor signaling along with tryptophan. Together 
this information has suggested that antigen-presenting 
cells can employ IDO1 to restrict T cell activation by 
blocking T cell proliferation, due to tryptophan 
catabolism. 
Apoptosis: The products of tryptophan catabolism by 
IDO1 include kynurenine and downstream products of 
the so-called kynurenine pathway that can induce 
apoptosis of thymocytes and Th1 but not Th2 helper T 
cells. Apoptosis induced by these products does not 
require Fas/Fas ligand interactions but are associated 
with activation of caspase-8 and the release of 
cytochrome c from mitochondria. When administered 
in vivo, some kynurenines can deplete specific 
thymocyte subsets like dexamethasone. Thus, the 
selective deletion of T lymphocytes by kynurenine 
production has been suggested as one mechanism 
through which tryptophan catabolism could blunt 
immunity under pathologic conditions. 
Immune tolerance: Many studies illustrate how IDO1 
overexpression can blunt immune responses to 
neoantigens. Cell lines overexpressing IDO1 limit 
antigen-specific T cell responses in vitro. In  
murine tumor cell lines, IDO1 overexpression renders 
tumor allografts resistant to immune rejection in vvo. 
Adenoviral-mediated IDO1 gene transfer into  
 
pancreatic islet cells is reported to prolong survival n  
allogeneic hosts. Similarly, ectopic expression of IDO1 
is found to protect allogeneic lung transplants from 
rejection. CTLA-4 signaling induces IDO and pre-
treatment of mice with CTLA-4-Ig to induce IDO 
expression suppresses rejection of pancreatic islet 
allografts. In a model of graft-versus-host disease, 
IDO1 overexpression completely blocks clonal 
expansion of alloreactive T-cell receptor (TCR)-
transgenic T cells. Studies in other tissue allograft 
models confirm that IDO is a potent regulator of 
adaptive immune response. A consistent picture is 
provided by studies employing the pharmacological 
agent 1MT as an IDO inhibitor. 1MT exacerbates 
symptoms of experimental autoimmune encephalo-
myelitis and abrogates the tolerogenic effects of 
CTLA4-Ig treatment in an islet-cell transplant model. 
Similarly, 1MT increases disease severity and mortality 
in a T cell-dependent colitis model, suggesting the rol  
of IDO in the downregulation of Th1 responses within 
the gastrointestinal tract. Lastly, as discussed in more 
detail below, 1MT corrects immune escape mediated 
by IDO in a variety of allograft and transgenic 
(autochthonous) mouse models of cancer. 
Maintenance of Pregnancy: IDO1 has been suggested 
to mediate immune tolerance during pregnancy on the 
basis of the ability of IDO inhibitor 1MT to act as n 
abortifacient in allogeneic but not syngeneic mice. 
IDO1 gene knockout studies do not replicate this effect 
suggesting a compensatory genetic effect or an IDO1-
dependent effect of 1MT. Indeed, 1MT is no longer 
active in IDO1 knockout mice, demonstrating that 1MT 
must target IDO1 mediate its effects. 
Null phenotype in mouse: IDO1-deficient mice are 
viable and fertile. in vitro generation of antigen-
presenting dendritic cells (DCs) from IDO1-deficient 
bone marrow precursors appeared to be affected in the 
presence of GM-CSF, however, changing growth factor 
and adherence conditions abolished the observed 
differences (Flt3L and low-adherence dishes). 
Moreover, IDO1-deficient mice display a normal DC 
compartment in vivo and do not develop lethal 
autoimmune or lymphoproli-ferative disorders. 
Consistent with this observation, mice treated 
systemically for up to 28 days with 1MT or other IDO 
inhibitors do not appear to develop spontaneous 
autoimmunity. Together these observations imply that
IDO1 is non-essential for self tolerance. In contrast, 
skin carcinogenesis studies reveal that IDO1-deficient 
mice are resistant to cancer initiation and carcinoma 
progression, due to an apparent inability to develop 
tumor tolerance. 
Homology 
Human IDO1 has 62% identity (77% similarity) with 
mouse IDO1 and 44% identity (64% similarity) with 
mouse IDO2. Human IDO1 has 44% identity (63% 
similarity) with human IDO2 and mouse IDO1 has 
44% identity (64% similarity) with mouse IDO2. 










IDO1 is observed to be highly expressed in many 
human cancers at the level of the tumor and/or the 
tumor-draining lymph node. Elevated tryptophan 
catabolism in the urine and blood of tumor-bearing 
patients has been recognized for many decades, perhaps 
explained by the discovery of common IDO1 
overexpression in tumors. 
Leukemia 
Note 
Patients with acute myeloid leukemia (AML) exhibit an
increased ratio of Kyn/Trp in the serum and patients 
with higher Kyn/Trp ratios display a dramatically 
reduced survival. In adult T-cell leukemia/lymphoma 
(ATLL) that is caused by HTLV-1 infection, the serum 
kynurenine concentrations, Kyn/Trp ratio, and level of 
IDO mRNA expression are all significantly increased 
relative to healthy subjects. Interestingly, after 
chemotherapy, serum kynurenine concentrations are 




IDO1 expression has been reported in all breast cancer 
and non-cancer specimens as determined by 
semiquantitative RT-PCR, with higher levels observed 
in cancer specimens compared to non-cancer 
specimens. In this malignancy IDO1 has not been 
found to correlate to histologic classification, tumor 
size, lymph nodes metastasis, and survival rate aftr 
surgery. However, its expression has been reported to 
correlate to clinical stage and the serum level of 
immunosuppressive acidic protein (IAP) in breast 
cancer patient. In MMTV-Neu transgenic mice, an 
established mouse model of breast cancer, the IDO1 
inhibitor 1MT slows tumor growth but does not arrest 
it. In contrast, 1MT cooperates strongly with paclitaxel, 
cisplatin, cyclophospha-mide, or doxyrubicin (all 
widely used in breast cancer treatment) to trigger 
regression of established tumors that are otherwise 
refractory to single-agent therapy. 
Lung cancer 
Note 
IDO1 expression has been reported to be higher in  
cases of lung cancer and autologous non-malignant 
lung tissues than in lung cancer cell lines by 
quantitative real-time RT-PCR. No significant 
correlations between IDO1 expression and clinico-
pathological parameters have been observed. In human 
non-small-cell lung cancer (NSCLC), 
immunohistochemical analysis suggests that IDO1 is 
expressed not by tumor cells but by eosinophilic  
granulocytes. IDO1 protein in NSCLC is enzy-
matically active, implying that IDO-positive 
eosinophils may be competent to exert local 
immunosuppression. A significant relationship is found 
between the amount of IDO1-positive infiltrate and 




In the classical two-stage mouse model of skin 
carcinogenesis, phorbol myristate acetate (PMA) 
induces plasmacytoid dendritic cells (pDCs) in loca 
draining lymph nodes to express IDO1, which confers 
suppressor activity to the pDCs. Significan-tly, IDO1-
deficient mice display a tumor-resistant phenotype in 
this model of carcinogenesis. 
Colon cancer 
Note 
IDO1 expression in human colon carcinoma cell lines 
dependent on IFN-gamma induction. Immuno-
histochemical analysis of colon tumors indicated that 
IDO1 overexpression is associated with a significant 
reduction of CD3+ infiltrating T cells and higher 
occurrence of liver metastases in colo-rectal cancer 
patients. Conversely, no correlation was seen with 
tumor stage, tumor size, histologic grade, nodal statu , 
gender, or age. 
Pancreatic ductal adenocarcinoma 
(PDA) 
Note 
IDO1 is upregulated in metastatic PDA cells and 
associated with an increased number of FoxP3+ T 
regulatory cells (Tregs) in tumors. No correlation f 
IDO1 expression is observed with tumor histologic 
grade in PDA. In contrast, while non-metastatic PDAs 
are negative or only focally positive for IDO1, higer 
and broader expression of IDO1 is seen in both primary 
and metastatic tumors in patients with lymph node 
metastases (with stronger staining in metastatic foci). 
Liver cancer 
Note 
In human hepatocarcinomas, immunohistochemical 
analysis revealed that IDO1 was strongly expressed in 
36% of cases and weakly expressed in 64% of cases 
examined. In this study, IDO1 overexpression was 
significantly correlated with high rates of metastasis 
and poor prognosis. 
Ovarian cancer 
Note 
IDO1 was found to be overexpressed in serous-type 
ovarian cancer where it was associated with decreased 
patient survival. IDO1 overexpression was also 
associated with resistance to paclitaxel. 
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Renal cell carcinoma 
Note 
Elevated levels of IDO1 mRNA were detected in >75% 
of clear cell type renal carcinoma, compared to normal 
kidney. In this study, IDO1 expression was associated 
with vascular cells in tumors and it correlated with 
improved long-term survival. 
Cervical cancer 
Note 
IDO1 is expressed in cervical intraepithelial neo-plasia 
(CIN) and invasive cervical cancer. Immuno-
histochemical analysis suggests IDO1 expression in 
antigen-presenting cells in both primary and invasie 
lesions. FoxP3+CD4+CD25+ Tregs appear in CIN and 
are increased in invasive cancer. No significant 
differences were observed in the proportion of Tregs in 
the stroma or epithelium (or between metastatic and
non-metastatic cancers), but there was a significant 
increase in Tregs associated with IDO1 overexrpression 
in metastatic lymph nodes as compared to non-
metastatic lymph modes. 
Endometrial cancer 
Note 
High expression of IDO1 correlated with a reduced 
number of tumor-infiltrating lymphocytes (TILs) and 
natural killer (NK) cells in endometrial cancer. IDO1 
overexpression was also positively correlated with 
myometrial invasion, nodal metastasis, and lymph-
vascular space involvement, all of which contribute to 




Primary uveal melanoma from tumor-bearing eyes and 
metastatic uveal melanoma from liver were not found 
to express IDO1 in situ. Also, IDO1 was not expressed 
in either primary or metastatic uveal melanoma cell 
lines unless they were stimulated by IFN-gamma. 
Addition of 1MT to IFN-gamma-treated uveal 
melanoma cell lines significantly diminished 
kynurenine levels. Together these findings suggested 
that in settings of IFN-gamma expression IDO1 
upregulation may promote escape from T cell-mediate 
immune surveilance in uveal melanoma. 
Inflammatory bowel disease (IBD) 
Note 
IDO1 mRNA is markedly induced in lesional colonic 
biopsies of IBD patients, being primarily expressed in 
CD123(+) mononuclear cells that infiltrate the 
submucosal areas of inflamed lesions. In Crohn's 
disease (CD), IDO1 is also strongly expressed in 
perifollicular regions of lymphoid follicles, with 
increased kynurenine and Kyn/Trp ratioes in colonic 
explant cultures (CECs) from CD patients. 
Immunohistochemical analysis of colonic biopsies 
taken from CD patients prior and after treatment with 
the TNF-blocking antibody infliximab caused a 
reduction in IDO1 expression in patients with good 
clinical response to infliximab, consistent with a 
potential benefit to IDO1 reduction in this disease. 
Primary biliary cirrhosis (PBL) 
Note 
PBL is a chronic autoimmune cholestatic liver disease 
characterized by inflammatory destruction of the small 
bile ducts within the liver that eventually leads to 
cirrhosis. One study found a defective Treg 
compartment and an impaired IDO1 induction by IFN-




Infection of HIV or Simian immunodeficiency virus 
(SIV) increases IDO1 expression and functional IDO 
enzymatic activity both in vitro and in vivo. It is 
reported that patients infected with HIV have 
chronically reduced levels of plasma tryptophan and 
increased levels of kynurenine, suggesting the 
possibility of IDO1 activation. IDO1-expressing cells 
may protect HIV from clearance by allowing virally 
infected cells to become resistant to attack by T cell, or 
indirectly by promoting induction of acquired, antigen-
specific tolerance to HIV antigens. 
Depression 
Note 
Evidence exists of a link between IDO activity and 
mood. In serotonergic nerve terminals tryptophan is 
hydroxylated before conversion to serotonin (5HT). 
Lower levels of serotonin in the brain are associated 
with depressed mood. Tryptophan availability limits de 
novo synthesis of serotonin and tryptophan depletion 
has been associated with depressive symptoms in 
patients with remitted major depressive disorder, 
resulting in a distur-bance of mood in subjects with a 
family history of affective illness. 
Given the proposed role of IDO in maintaining 
pregnancy, the linkage between IDO activity and mood 
may be relevant to postpartum depression. Typically 
this phenomenon occurs within a few days after 
delivery until the tenth day postpartum. An association 
has been noted between Kyn/Trp ratio and the severity 
of depressive symptoms in the early puerperium, 
suggesting that an increased degradation of typtophan 
relates to the occurrence of postpartum blues. 
Conversely, a decrease in Kyn/Trp ratioes has been 
reported in women with stable mood after delivery. 
Some evidence exists that inflammatory changes in the 
brain that may be associated with IDO1 expression are 
pathological features of both depression and dementia. 
Pathological changes have been associated with a 
reduction in the neuroprotective components of the 
kynurenine pathway (e.g. kynurenic acid) and an 
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increase in the neurodegenerative components (e.g. 3-
hydroxy-kynurenine acid and quinolinic acid). These 
changes are postulated to cause neuronal damage and 
predispose chronically depressed patients to dementia. 
In Alzheimer's patients, plasma Kyn/Trp ratioes have 
been observed to correlate with the degree of cognitive 
deficit. Also, immunohisto-chemical analysis suggests 
that IDO1 is abundant in the brains of Alzheimer's 
patients compared to controls. Similarly, relative 
elevations in Kyn/Trp ratio have been found in plasm  
from patients with Huntington's or Parkinson's disease 
compared to controls. Notably, depressive symptoms 
affect up to 50% of Alzheimer's patients, 41% of 
Huntington's patients, and 40% of Parkinson's patients. 
Further support for a link between IDO1 elevation and 
depressed mood are found in patients with autoimmune 
diseases, where symptoms have been associated with 
increased tryptophan catabolism. Enhanced tryptophan 
degradation was found in systemic lupus 
erythromatosus, rheumatoid arthritis, sarcoidosis, and a 
mouse model of multiple sclerosis. It has also been 
noted that a higher proportion of patients infected with 
Hepatitis C virus (HCV) have lower serum tryptophan 
concentrations and depression relative to healthy 
volunteers. 
Defense against mycoplasm infection 
Note 
IDO1 has been implicated in host defence against 
certain pathogens such as Chlamydia pneumoniae, 
Toxoplasma gondii, group B streptococci, and 
mycobacteria through its ability to deplete trypto-han 
and thereby inhibit pathogen replication. IDO1 has also 
been observed to inhibit the replication of 
cytomegalovirus and herpes simplex virus in vitro. 
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